Does rivaroxaban reduce the incidence of venous thromboembolism or death due to venous thromboembolism in high-risk ambulatory patients with cancer?
High-risk ambulatory patients with cancer
Rivaroxaban
Composite of venous thromboembolism or death due to venous thromboembolism in the 180-day trial periodcomposite
Rivaroxaban did not significantly reduce the 180-day incidence of VTE or VTE-related death in high-risk ambulatory cancer patients, though events were lower during the active intervention period.
In high-risk ambulatory patients with cancer, treatment with rivaroxaban did not result in a significantly lower incidence of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period. During the intervention period, rivaroxaban led to a substantially lower incidence of such events, with a low incidence of major bleeding. (Funded by Janssen and others; CASSINI ClinicalTrials.gov number, NCT02555878.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Alok A. Khorana
Gerald A. Soff
Ajay K. Kakkar
New England Journal of Medicine
University of Washington
Johns Hopkins University
Cornell University
Building similarity graph...
Analyzing shared references across papers
Loading...
Khorana et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d56dc475589c71d767d067 — DOI: https://doi.org/10.1056/nejmoa1814630